Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001181431-09-041712
Filing Date
2009-08-28
Accepted
2009-08-28 17:41:33
Documents
2
Period of Report
2009-08-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 - BOOTH rrd251435.html 3  
1 FORM 3 - BOOTH rrd251435.xml 3 2186
2 POWER OF ATTORNEY rrd225204_254664.htm EX-24.1 3260
  Complete submission text file 0001181431-09-041712.txt   7238
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3344 N. TORREY PINES COURT, SUITE 200 LA JOLLA CA 92037
Business Address
Booth Mark D (Reporting) CIK: 0001470885 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33415 | Film No.: 091044149